Comparative Pharmacology
Head-to-head clinical analysis: AMIPAQUE versus SCANLUX 370.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIPAQUE versus SCANLUX 370.
AMIPAQUE vs SCANLUX-370
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metrizamide, a non-ionic iodinated contrast agent, attenuates X-rays due to iodine content, enhancing radiographic imaging. It distributes in extracellular fluid and does not cross intact blood-brain barrier; in subarachnoid space, it outlines neural structures.
Radiopaque contrast agent that contains iodine, attenuates X-rays, enhancing vascular and tissue visualization during imaging.
200-300 mg iodine/kg body weight intravenously, maximum 60 g iodine per administration.
The typical adult dose of SCANLUX-370 is 0.1 mg/kg administered intravenously as a single dose, up to a maximum of 7 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in patients with normal renal function; may be prolonged in renal impairment (up to 20-30 hours in severe renal failure).
The terminal elimination half-life of SCANLUX-370 is approximately 1.5-2 hours in patients with normal renal function. This short half-life allows for rapid clearance and minimal accumulation with repeated dosing.
Primarily renal excretion via glomerular filtration; approximately 90-95% of the dose is excreted unchanged in urine within 24 hours. Less than 5% is excreted in feces via biliary route.
SCANLUX-370 is primarily eliminated via renal excretion, with approximately 85-90% of the dose recovered unchanged in urine within 24 hours. The remaining 10-15% is excreted unchanged in feces via biliary elimination.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent